{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:04:14Z","timestamp":1789542254689,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia (AML), accounts for 5\u201320% of AML and carries a high risk of early, often hemorrhagic, mortality related to disseminated intravascular coagulation (DIC). With all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), APL has become highly curable, with survival approaching 90%. Data from Palestine are limited. This study addresses an important regional data gap by describing the presentation, complications, and outcomes of adults with APL treated at a tertiary Palestinian cancer center and by comparing patients with and without early death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 30 adults (\u226518 years) diagnosed with APL at An-Najah National University Hospital (NNUH), West Bank, Palestine, between January 2016 and June 2024. Patients were classified as standard-risk (WBC \u226410\u00d710\u2079\/L) or high-risk (WBC &gt;10\u00d710\u2079\/L). Standard-risk patients received ATRA+ATO induction, whereas high-risk patients received ATRA plus anthracycline-based induction. Consolidation with ATRA+ATO was given to patients who proceeded to consolidation in both groups. Early death was defined as death within 30 days of diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 15 males and 15 females, with a median age of 37 years (range, 18\u201379 years); 22 (73.3%) were standard-risk and 8 (26.7%) were high-risk. Median baseline values were hemoglobin 9.0 g\/dL, WBC 4.8\u00d710\u2079\/L, platelets 18.1\u00d710\u2079\/L, ANC 0.95\u00d710\u2079\/L, PT 17.2 s, aPTT 27.45 s, fibrinogen 142.5 mg\/dL, and D-dimer 30.9 mg\/L FEU. Early death occurred in 13.3% (4\/30) and was hemorrhage-related in the setting of coagulopathy\/DIC. All patients who survived beyond 30 days achieved complete hematologic remission. Kaplan\u2013Meier overall survival was 96.4% at 1 year and 87.7% at 2 years; median overall survival was 56.2 months (95% CI, 33.6\u201378.9). Compared with patients without early death, those with early death had higher admission WBC counts, longer aPTT, and more frequent ICU admission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-center Palestinian cohort, ATRA-based treatment yielded high remission rates and no observed relapse during follow-up. Early mortality remained the main barrier to cure and occurred in patients presenting with a higher leukocyte burden and evidence of more severe coagulopathy. Prompt diagnosis, immediate ATRA initiation, and intensive supportive care remain essential in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16031-0","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:29:58Z","timestamp":1776688198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and treatment outcomes of adult acute promyelocytic leukemia in the West Bank of Palestine: a single center retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Raghad","family":"Tanbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Ishtayeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Khaled","family":"Alhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"16031_CR1","unstructured":"Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. (1520\u20134383 (Electronic))."},{"key":"16031_CR2","doi-asserted-by":"crossref","unstructured":"Infante JA-O. Predictors of Early Death in Acute Promyelocytic Leukemia. LID\u2009\u2013\u200910.3390\/medsci13040300 [doi] LID\u2009\u2013\u2009300. (2076\u20133271 (Electronic)).","DOI":"10.3390\/medsci13040300"},{"key":"16031_CR3","unstructured":"Mitwalli S, Hammoudeh W, Giacaman R, Harding R. Access to advanced cancer care services in the West Bank-occupied Palestinian territory. (2234-943X (Print))."},{"key":"16031_CR4","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (1528-0020 (Electronic))."},{"key":"16031_CR5","unstructured":"Taylor FB Jr., Hoots TCF WK, Hoots Wk Fau -, Wada H, Wada H, Fau - Levi M, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. (0340\u20136245 (Print))."},{"key":"16031_CR6","unstructured":"Watts JM, Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? (1532\u20131681 (Electronic))."},{"key":"16031_CR7","unstructured":"Coutre S. Classification and risk stratification for acute promyelocytic leukemia. (2152\u20132669 (Electronic))."},{"key":"16031_CR8","unstructured":"Goodyear Md Fau -, Krleza-Jeric K, Krleza-Jeric K, Fau - Lemmens T, Lemmens T. Declaration Helsinki. (1756\u2013833 (Electronic))."},{"key":"16031_CR9","unstructured":"Rego EM. Kim Ht Fau - Ruiz-Arg\u00fcelles GJ, Ruiz-Arg\u00fcelles Gj Fau - Undurraga MS, Undurraga Ms Fau - Uriarte MdR, Uriarte Mdel R Fau - Jacomo RH, Jacomo Rh Fau - Guti\u00e9rrez-Aguirre H, Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. (1528-0020 (Electronic))."},{"key":"16031_CR10","unstructured":"Rego EM, Kim HF, Ruiz-Arg\u00fcelles GJ. Ruiz-Arg\u00fcelles Gj Fau - Uriarte MdR, Uriarte Mdel R Fau - Jacomo RH, Jacomo Rh Fau - Guti\u00e9rrez-Aguirre H, Guti\u00e9rrez-Aguirre H Fau - Melo RAM, The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). (1607\u20138454 (Electronic))."},{"key":"16031_CR11","unstructured":"Lo-Coco F, Avvisati G, Fau - Vignetti M, Vignetti M, Fau - Thiede C, Thiede C, Fau - Orlando SM, Orlando Sm Fau -, Iacobelli S, Iacobelli S, Fau - Ferrara F et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (1533\u20134406 (Electronic))."},{"key":"16031_CR12","unstructured":"Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. (1474\u20135488 (Electronic))."},{"key":"16031_CR13","unstructured":"Sanz MA-O, Fenaux P, Tallman MS, Estey EH, L\u00f6wenberg B, Naoe T et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. (1528-0020 (Electronic))."},{"key":"16031_CR14","unstructured":"Zapata-Canto N, Aguilar M, Arana L, Montano E, Ramos-Penafiel C, De la Pena JA et al. Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico. (1927\u2009\u2013\u20091220 (Electronic))."},{"key":"16031_CR15","unstructured":"Gill H, Raghupathy R, Lee CYY, Yung Y, Chu HT, Ni MY et al. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. (1471\u20132407 (Electronic))."},{"key":"16031_CR16","unstructured":"Paras G, Othus M, Schonhoff K, Shaw C, Sorror MA-O, Halpern AA-O et al. Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. (1476\u20135551 (Electronic))."},{"key":"16031_CR17","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P et al. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. (2374\u2013445 (Electronic))."},{"key":"16031_CR18","unstructured":"Patel RA-O, Patel DA-O, Patel MA-O, Ohemeng-Dapaah JA-O, Onyechi AA-O, Patel ZA-O et al. Disseminated Intravascular Coagulation in Acute Promyelocytic Leukemia Patients: A Retrospective Analysis of Outcomes and Healthcare Burden in US Hospitals. (1308\u20135263 (Electronic))."},{"key":"16031_CR19","unstructured":"Falanga A, Russo L, Tartari CJ. Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia."},{"key":"16031_CR20","unstructured":"Silva WFD Jr., Rosa LID, Marquez GL, Bassolli L, Tucunduva L, Silveira DRA et al. Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil - Early Deaths Are Still a Problem. (2152\u2013669 (Electronic))."},{"key":"16031_CR21","unstructured":"Park JH, Qiao B, Fau - Panageas KS. Panageas Ks Fau - Schymura MJ, Schymura Mj Fau - Jurcic JG, Jurcic Jg Fau - Rosenblat TL, Rosenblat Tl Fau - Altman JK, Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. (1528-0020 (Electronic))."},{"issue":"21","key":"16031_CR22","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1182\/blood.V120.21.3542.3542","volume":"120","author":"JM Norgaard","year":"2012","unstructured":"Norgaard JM, Ostgard LSG, Kjeldsen E, Holm MS, Kjeldsen L, Kallenbach M, et al. High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study. Blood. 2012;120(21):3542.","journal-title":"Blood"},{"issue":"4","key":"16031_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bjhh.2016.08.002","volume":"38","author":"E Crespo-Solis","year":"2016","unstructured":"Crespo-Solis E, Contreras-Cisneros J, Demichelis-Gomez R, et al. Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol. Rev Bras Hematol Hemoter. 2016;38(4):285\u201390.","journal-title":"Rev Bras Hematol Hemoter"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16031-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:25:23Z","timestamp":1781648723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16031-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16031"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16031-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8456765\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Ethics Committee of An-Najah National University Hospital, Nablus, Palestine, in 2023, in line with national regulations and the principles of the Declaration of Helsinki (1964) and its subsequent amendments. Owing to the retrospective design and use of anonymized data, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"695"}}